Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

Utz Krug, Anja Koschmieder, Daniela Schwammbach, Joachim Gerss, Nicola Tidow, Björn Steffen, Gesine Bug, Christian H Brandts, Markus Schaich, Christoph Röllig, Christian Thiede, Richard Noppeney, Matthias Stelljes, Thomas Büchner, Steffen Koschmieder, Ulrich Dührsen, Hubert Serve, Gerhard Ehninger, Wolfgang E Berdel and Carsten Müller-Tidow

PLOS ONE, 2012, vol. 7, issue 12, 1-8

Abstract: Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML. Trial Design: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size. Patients and Methods: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of

Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052695 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 52695&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0052695

DOI: 10.1371/journal.pone.0052695

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().